TP53 and breast carcinoma: The uniqueness of this case lies in the specific combination of HER2-positive breast cancer, the development of PDAC, the absence of canonical hereditary mutations, and the finding of multiple VUS in conjunction with somatic TP53 mutations in both tumors.